Candida albicans phosphomannan complex as a vaccine

• US 6,488,929 B2
• Filed: 07/12/1999
• Issued: 12/03/2002
• Est. Priority Date: 05/23/1994
• Status: Expired due to Fees

• Current Assignee: Montana Inc.
• Original Assignee: Montana State University
• Inventors: Cutler, Jim E., Han, Yongmoon
• Primary Examiner(s): DUFFY, PATRICIA ANN
• Application Number:
  US09/351,630
• Publication Number:
  US 20020160009A1
• Time in Patent Office: 1,240 Days
• Field of Search: 530/388.1, 530/387.1, 530/387.5, 530/388.2, 530/388.5, 530/389.1, 530/389.5, 424/137.1, 424/141.1, 424/152.1
• US Class Current: 424/137.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0002 Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: C07K 14/40 from Candida
• CPC Class Codes: C07K 16/14 against material from fungi, algea or lichens
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to the infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.

Claims

1. A therapeutic composition for the passive treatment of candidiasis comprising a pharmaceutically effective amount of antibodies that bind to β

-1,2-linked tri-mannose residues of the mannan portion of the phosphomannoprotein complex of Candida albicans and a pharmaceutically acceptable carrier.

2. The therapeutic composition of claim 1, wherein the antibodies are monoclonal antibodies.

3. The therapeutic composition of claim 1, wherein the antibodies are pools of monoclonal antibodies.

4. The therapeutic composition of claim 1, wherein the antibodies are polyclonal antibodies.

5. The therapeutic composition of claim 1, wherein said candidiasis is disseminated candidias is or mucocutaneous candidiasis.

7. A method of passive immunization against candidiasis comprising the step of administering to a patient in need thereof the composition of any one of claims 1-3.

8. The method of claim 1, wherein said candidiasis is disseminated candidiasis or mucocutaneous candidiasis.

6. A passively immunizing monoclonal antibody that binds to 1,2-linked trimannose residues of the mannan portion of the phosphomannoprotein complex of Candida albicans.